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Background: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of meso-
thelial origin associated with asbestos exposure. MPM has a limited response to conventional
chemotherapy and radiotherapy so early diagnosis of MPM is very important. Vascular endothe-
lial growth factor (VEGF), a potent mitogen for the vascular endothelium, is also known to be
an autocrine growth factor for MPM. Here, we investigated the pleural effusion VEGF levels in
patients with MPM and compared them to those of a population with a non-malignant pleuritis
or lung cancer involving malignant pleural effusion.
Methods: The pleural effusion VEGF concentrations were measured in 46 MPM patients and 45
individuals with non-MPM individuals (25 individuals with non-malignant pleural effusions, and
20 individuals with lung cancer involving malignant pleural effusion).
Results: We demonstrated that patients with MPM had significantly higher pleural effusion VEGF
levels than a population with non-malignant pleuritis or lung cancer involving malignant pleural
effusion, and the patients with advanced stage MPM showed higher levels of VEGF than the early
stage MPM patients. The difference in overall survival between the groups with pleural effusion
VEGF levels lower and higher than the assumed cut-off of 2000 pg/ml was significant.
Conclusions: Our data suggest that the pleural effusion VEGF concentration could be useful as an
aid for the diagnosis of MPM and as a prognostic factor.
ª 2010 Elsevier Ltd. All rights reserved.OC curve; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; MPM,
F, platelet derived growth factor; ROC, receiver operating characteristic; TGF, transforming growth
wth factor.
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138 N. Hirayama et al.Introduction diagnosis of MPM using histopathological samples. AllMalignant pleural mesothelioma (MPM) is an aggressive
malignant tumor of mesothelial origin associated with
asbestos exposure.1e3 Although asbestos usage has recently
decreased in Western countries and Japan, the incidence of
MPM is expected to markedly increase over the next few
decades because there is the long latency period (20e40
years) between asbestos exposure and tumor development.4
MPM shows limited response to conventional chemotherapy
and radiotherapy. Although the multi-targeted anti-folate
pemetrexed has recently been approved as a first-line agent
in combination with cisplatin for the treatment of MPM,
overall survival remains very poor5 with a median survival
duration of 8e18 months.6 In several centers, potentially
curative surgery combined with some form of adjuvant
therapy has been performed. Such early therapeutic inter-
vention seems to be more beneficial than late intervention.
Therefore, diagnosing MPM early is very important.1
However, cytological diagnosis of pleural effusions can
often be very difficult in MPM because MPM cells can not be
easily distinguished from lung cancer cells and sometimes
they can not be detected in pleural effusions.1 Pleural
effusion biomarkers for MPM such as hyaluronic acid and
CYFRA 21-1 have been reported and used to assist the
diagnosis of MPM.7, 8 To further improve the specificity and
sensitivity of diagnosis, research into the development of
novel biological markers is urgently required.
Tumor growth and metastasis are associated with angio-
genesis. We previously reported that vascular endothelial
growth factor (VEGF), a potent mitogen for the vascular
endothelium, is associated with bleomycin-induced pulmo-
nary fibrosis in mice.9 MPM is a malignant transformation of
mesothelial cells, which originate from mesenchymal cells
similar to lung fibroblasts. Moreover, we recently reported
that patients with MPM had significantly higher serum levels
of VEGF than apopulationwith a history of asbestos exposure
without developing MPM, which suggested its usefulness as
a marker for MPM.10 In this study, we evaluated the clinical
role of pleural effusion VEGF levels in MPM and found that
patients with MPM had significantly higher pleural effusion
VEGF levels than a population with a non-malignant pleuritis
or lung cancer involving malignant pleural effusion, which
suggested its usefulness as a marker for MPM. Our results are
consistent with previous reports demonstrating that VEGF is
expressed in MPM, and moreover, that it acts as an autocrine
growth factor for MPM.11
Materials and methods
Patients and pleural effusion samples
We studied the VEGF levels in pleural effusions collected
from 91 individuals presenting at the Department of Respi-
ratory Medicine of Hyogo College of Medicine Hospital from
2005 to 2009. The pleural effusions were obtained by thor-
acocentesis. All patients were diagnosed by pathologists,
and it was confirmed that their clinical course matched their
diagnosis. Forty-six individuals had malignant pleural meso-
thelioma involving a documented asbestos exposure history.
These cases were diagnosed by pathologists skilled in thepatients were classified using the staging system of the
International Mesothelioma Interest Group (IMIG).12 Patients
with MPM were treated according to our therapeutic guide-
line: combination chemotherapy including multi-targeted
anti-folate pemetrexed was performed for patients with PS
0e1 and age< 70, and for the remainders, best supportive
care was chosen. Surgical treatment was not performed for
the patients in the present study. Twenty-five individuals had
non-malignant pleural effusions, and 20 individuals had lung
cancer involving malignant pleural effusion. The study was
approved by our ethics committee in accordance with the
1975 Declaration of Helsinki. Informed consent was obtained
from all patients. Fresh pleural effusion samples were
collected before treatment and centrifuged for 10 min at
2000 g, before the resultant supernatants were immediately
frozen in liquid nitrogen and stored at 80 until use.
Measurement of VEGF
The VEGF concentrations of the pleural effusions were
measured using an enzyme-linked immunosorbent assay
(ELISA) Kit (R&D Systems, Oxford, UK) according to the
manufacturers’ instructions.
Statistical analysis
The nonparametric ManneWhitney U-test was used to
compare two groups of samples. Comparisons of data
between various groups were performed with the
nonparametric KruskaleWallis test followed by the Man-
neWhitney U-test. In all tests, a p-value <0.05 was
considered significant. In order to estimate the significance
of the pleural effusion VEGF values, receiver operating
characteristic (ROC) curves, the area under the ROC curve
(AUC), and their 95% confidence intervals (95% CI) were
calculated using standard techniques. To examine the cut-
off values for the pleural effusion VEGF levels, we calcu-
lated the total sensitivity and specificity for each cut-off
value and then chose the cut-off values that maximized
each factor. Correlations between data were analyzed
using Spearman’s rank correlation test. Estimates of the
probability of survival were calculated by the KaplaneMeier
method and compared using the log-rank test. In order to
evaluate the prognostic significance of VEGF on the survival
of patients with MPM, Cox’s proportional hazards regression
analysis was carried out as a multivariate analysis.Results
VEGF pleural effusion levels in patients with MPM
and individuals with non-MPM
We recruited a total of 91 subjects suffering from pleural
effusion. Of them, 46 had confirmed MPM, 25 had no
malignant pleural effusion, and 20 had lung cancer
involving malignant pleural effusion. Their characteristics
are shown in Table 1.
The ROC curves for the pleural effusion VEGF levels
showed that the patients with MPM had an AUC of 0.8304 in
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(95% CI: 0.7528e0.9081). At the optimal cut-off value of
2000 pg/ml, the diagnostic sensitivity was 71.7%, and the
specificity was 76.0% (Fig. 1A). The mean pleural effusion
VEGF concentration of the patients with MPM was signifi-
cantly higher (5303.6 1711.0 pg/ml) than that of the
patients with non-malignant pleural effusion and the
patients with lung cancer involving malignant pleural effu-
sion (1172.2 1212.8 pg/ml, 2429.9 2173.8 pg/ml)
(pZ 0.0003, pZ 0.0017, respectively) (Fig. 1B). Moreover,
scatter plots of the pleural effusion VEGF levels of the MPM
patients showed statistically significant tendencies to
increase as the stage increased (stage I: 1919.2 1802.8 pg/
ml, stage II: 3764.0 2432.0 pg/ml, stage III:
3956.7 2316.5 pg/ml, and stage IV: 4789.8 2281.3 pg/ml)
(pZ 0.025, Fig. 1C). There were no statistically significant
differences between the pleural effusion VEGF levels of the
MPMhistological groups (epithelioid: 4000.0 2499.3 pg/ml,
non-epithelioid: 4185.3 2245.5 pg/ml) or sex (male:
4253.9 2381.9 pg/ml, female: 3070.6 2470.9 pg/ml),
and there were no significant differences in the pleural
effusion VEGF levels between the subjects with benign
asbestos pleurisy and those with benign pleurisy without
a history of asbestos exposure (1853.8 1438.7 pg/ml,
1139.6 1223.5 pg/ml, respectively).
Correlation of VEGF levels between pleural
effusions and serum
We examined pleural effusion and serum VEGF levels in 16
MPM patients and showed that there was a significant
correlation between them (rZ 0.51, pZ 0.046, Fig. 2).Table 1 Characteristics of the MPM patients and non-malignan
MPM
Age 69.17 9.64
Sex Male/Female
Histology Epithelioid
Sarcomatoid
Biphasic
Stage I/II/III/IV
No-malignancy
Age 70.50 13.02
Sex Male/Female
Benign asbestos pleurisy
Tuberculous(Tb) pleurisy
Infectious (non-Tb) pleurisy
Para-pneumonic
Heart failure
Hepatic failure
Renal failure
Lung cancer
Age 69.00 8.84
Sex Male/Female
Adenocarcinoma
Squamous cell
SmallThe numbers of MPM patients with higher VEGF levels in
both their serum and pleural effusion; higher VEGF levels in
their serum alone; higher VEGF levels in their pleural
effusion alone; and levels lower than 460 pg/ml (serum cut-
off level) and 2000 pg/ml (cut-off level for pleural effusion)
in the serum and pleural effusion, respectively,10 were 7, 5,
2, and 2, respectively. The two MPM patients with lower
VEGF levels in both their serum and pleural effusion were
classified as stage I.
Relationship between pleural effusion VEGF levels
and overall survival
Among the 46 MPM patients, we were able to follow 28
patients closely for up to 600 days. To study the relationship
between the pleural effusion VEGF levels and the patients’
clinical courses,we separated the patients according to their
pleural effusion VEGF levels at the time of the first
measurement. The first group included patients with pleural
effusion VEGF levels of lower than 2000 pg/ml (the cut-off
value that we chose). In this group of 11 patients, the mean
VEGF value was 1070.2 pg/ml (interquartile range:
634.3e1498.4). The other group included the remaining 17
patients with pleural effusion VEGF levels of higher than
2000 pg/ml, whosemean VEGF value of pleural effusions was
5101.1 pg/ml (interquartile range: 3184.9e6311.4). The
difference in overall survival between the groups with lower
and higher pleural effusion VEGF values than the assumed
cut-off point of 2000 pg/ml was significant (pZ 0.041,
Fig. 3). Cox’s regression analysis was performed on 28 MPM
patients for whomdata on age, sex, histology, stage, and the
pleural effusion VEGF level were available. Independentt subjects.
Cases (%) Total
38(82.6)/8(17.4) 46
34(73.9)
10(21.7)
2(4.4)
8(17.5)/6(13.0)/6(13.0)/26(56.5)
21(84.0)/4(16.0) 25
5(20.0)
8(32.0)
8(32.0)
1(4.0)
1(4.0)
1(4.0)
1(4.0)
10(50.0)/10(50.0) 20
17(85.0)
2(10.0)
1(5.0)
Figure 1 Pleural effusion VEGF levels in patients with MPM
and non-MPM subjects. (A) An analysis that included 46 MPM
and 25 non-malignant pleural effusion patients revealed an
area under the curve (AUC) of 0.8304 (95%CI: 0.7528e0.9081).
At the optimal cut-off value of 2000 pg/ml, the diagnostic
sensitivity was 71.7%, and the specificity was 76.0%. (B) The
pleural effusion VEGF levels of the patients with MPM versus
those of the patients with non-malignant pleural effusion or
lung cancer involving malignant pleural effusion were
measured as described in Materials and Methods. (C) The
pleural effusion VEGF levels in the MPM patients divided into 4
stages are shown. The nonparametric ManneWhitney U-test (B)
or the nonparametric KruskaleWallis test followed by the
ManneWhitney U-test (C) was used. p-values <0.05 were
considered significant. The horizontal bars represent the mean
of each group. The cut-off value is shown as a horizontal line.
Figure 2 Correlation of VEGF levels between pleural effu-
sions and sera. We examined the pleural effusion and serum
VEGF levels in 16 MPM patients and showed that there was
a significant correlation between the two (rZ 0.51,
pZ 0.046). Correlations between data were analyzed using
Spearman’s rank correlation test.
Figure 3 Survival of MPM subjects according to pleural
effusions VEGF levels. Estimates of the probability of survival
were calculated using the KaplaneMeier method and compared
using the log-rank test.
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found for age (65  versus< 65years; HR, 15.6; 95% CI,
1.068e229.125; pZ 0.045), sex (male versus female; HR,
0.380.0031; 95% CI, 0.000062e0.1555; pZ 0.0038),
histology (sarcomatoid versus epithelioid; HR, 8.663; 95% CI,
1.114e67.351; pZ 0.0039), and pleural effusion VEGF level
(2000  versus< 2000 pg/ml; HR, 961.23; 95% CI,
7.083e130446.4; pZ 0.0061).Discussion
MPM is a malignant transformation caused by the exposure
of mesothelial cells to asbestos, which shows a limited
response to conventional chemotherapy and radiotherapy,
and its prognosis is very poor. The lifetime risk of MPM is
associated with occupational and/or environmental
asbestos exposure history.13 Due to the long latency period
(typically longer than 30 years) between the first asbestos
exposure and the onset of the disease, MPM remains
a universally fatal disease of increasing incidence all over
the world.1, 2
Although in advanced cases, resection of the tumor only
prolongs survival by about 3 months, patients with stage IA
disease survive for five or more years after total resection
of the tumor.14 Due to the difficulty of the differential
diagnosis of MPM among individuals with pleural effusion by
radiological, cytological, and/or histological examinations,
efficient and practical pleural effusion biomarkers are
required to aid the diagnosis of MPM. To date, there have
been several reports concerning candidates for clinically
useful markers for MPM.14e17 Indeed, the level of meso-
thelin-related protein (SMRP), the soluble form of meso-
thelin, has been reported to be a useful pleural effusion
marker in MPM.18 Mesothelin is thought to play a role in
cell-adhesion, cell-to-cell recognition, and signaling;
however, its biological functions in MPM cells have not been
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between pleural effusion mesothelin levels and survival in
MPM patients.18
Therefore, it is important to find biological markers with
effects on MPM cells that are closely related to MPM
progression. MPM cells are known to exhibit increased and/
or dysregulated growth. Several factors, including trans-
forming growth factor (TGF)-b1, platelet derived growth
factor (PDGF), TGF-a, and interleukin (IL)-8, have been
reported to be associated with MPM cells.19e24 Moreover,
tumor development is closely related to angiogenesis.
Malignant tumors require new blood vessel formation, and
it has been reported that increased vascularity in MPM is
associated with a poor prognosis.2, 25 VEGF is known to be
an important regulator of angiogenesis and plays critical
roles in endothelial cell proliferation, vascular perme-
ability, and angiogenesis in several inflammatory
lesions.26e28 We previously reported that VEGF is associated
with bleomycin-induced pulmonary fibrosis in mice.9 MPM is
a malignant transformation of mesothelial cells, which
originate from mesenchymal cells similar to lung fibro-
blasts, so it would not be surprising if VEGF was found to be
associated with MPM progression. Moreover, we recently
reported that patients with MPM had significantly higher
serum levels of VEGF than a population with a history of
asbestos exposure, which suggested its usefulness as
a marker for MPM. In this study, we evaluated the clinical
role of VEGF as a pleural effusion biomarker in MPM and
found that patients with MPM had significantly higher
pleural effusion VEGF levels than a population with non-
malignant pleural effusion or lung cancer involving malig-
nant pleural effusion.
Paracrine and autocrine mechanisms have been reported
for several cytokines in malignant tumors. We recently
reported the autocrine and/or paracrine mechanism of
TGF-b1 in MPM.
19 VEGF has also been reported to be an
autocrine growth factor of MPM.11, 29 On the other hand, Li
et al.30 reported that treatment with anti-VEGF neutral-
izing antibody suppressed MPM progression in a mouse
model, mainly by preventing angiogenesis, especially
during the formation of pleural effusion. These reports
suggested that VEGF plays an important role in the tumor
growth of MPM. Strizzi et al.11 reported that higher VEGF
levels were found in the pleural effusions of MPM patients
than in those of patients with non-malignant pleural
diseases; however, there was no significant correlation
between VEGF levels and MPM patient survival. In the
present study, we demonstrated that patients with MPM
had significantly higher pleural effusion VEGF levels than
a population with non-malignant pleuritis or lung cancer
involving malignant pleural effusion, and moreover, there
was a significant correlation between VEGF levels and MPM
patient survival. The discrepancy between our observations
and those of the previous study with regard to the corre-
lation between VEGF pleural effusion levels and MPM
patient survival may be explained as follows: first, they
examined 12 MPM patients; whereas, we examined more
patients; second, their MPM patients were classified into IA
(nZ 1), IB (nZ 5), II (nZ 5), and III stages (nZ 1);
whereas, our patients included more advanced stages.
Here, we examined the pleural effusion and serum VEGF
levels in 16 MPM patients and demonstrated that there wasa significant correlation between them. In these patients,
14 patients showed higher VEGF levels in their serum and/
or pleural effusion. On the other hand, 12 and 9 patients
had higher VEGF levels in their serum and pleural effusion,
respectively. Only 2 stage I patients demonstrated lower
VEGF levels in both their serum and pleural effusion. So the
measurement of VEGF levels in both serum and pleural
effusions seems to be an efficient way of diagnosing MPM.
The prognostic significance of VEGF in MPM has been
estimated previously.31 However, the previous study
demonstrated a significant correlation between the VEGF
staining of resected specimens and short survival. In the
present study, we demonstrated that pleural effusion VEGF
levels gradually increased according to the progression of
the disease, and the KaplaneMeier method revealed
a significant correlation between pleural effusion VEGF
levels and survival, which suggested its usefulness as
a marker for estimating prognosis.
Conclusion
In summary, we demonstrated that patients with MPM had
significantly higher pleural effusion VEGF levels than
a population with non-malignant pleuritis involving benign
asbestos pleurisy or lung cancer involving malignant pleural
effusion, suggesting VEGF to be a useful marker for MPM.
The patients with advanced stage MPM showed higher levels
of VEGF than the patients with early stage MPM, and the
KaplaneMeier method revealed a significant correlation
between pleural effusion VEGF levels and patient survival.
Moreover, Cox’s regression analysis demonstrated that the
pleural effusion VEGF level had an independent statistically
significant prognostic effect on survival, which suggested its
usefulness as a marker for estimating prognosis.Acknowledgements
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